Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

- LP-184 treatment induced tumor regression evidenced by over 106% tumor growth inhibition - LP-184 reduced xenograft tumor volume in mice by greater than 85% within the treatment group - LP-184 resulted in a statistically significant (p < 0.0001) extension of median overall survival compared to the control group - Lantern extends R&D collaboration with Johns Hopkins University into next phase with focus on areas of high patient need in GBM

Daniel Carlson

August 19, 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.